[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-adenocarcinoma":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,92,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100647256","phase-1-dbc-664-in-adult-patients-with-solid-tumors-100647256",false,"NCT07705035","DBC-664 in Adult Patients With Solid Tumors","A Phase 1a\u002F1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Must be ≥18 years of age at the time consent is signed.\n* Has a histologically or cytologically confirmed unresectable recurrent locally advanced or metastatic solid tumor\n* Has measurable disease per RECIST v1.1 (or mRECIST 1.1 for patients with pleural mesothelioma), as assessed by the local site Investigator\u002Fradiology.\n\nExclusion Criteria:\n\n* Has a diagnosis of immunodeficiency.\n* Has had a prior stem cell, bone marrow, or organ transplant.\n* Has a known history of human immunodeficiency virus (HIV) infection.\n* Has active or chronic hepatitis B virus (HBV), or hepatitis C virus (HCV) infection.\n* Has an active autoimmune disease (non-immunotherapy induced conditions) that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).\n* Has a history of (noninfectious) pneumonitis that required steroids or current active pneumonitis\u002Finterstitial lung disease.\n* Has symptomatic visceral spread of disease that poses a risk of life-threatening complications in the short term, per Investigator's opinion (including massive uncontrolled effusions \\[pleural, pericardial, peritoneal\\], pulmonary lymphangitis, and over 50% liver involvement).\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Individuals with previously treated CNS metastases may participate provided they are radiologically stable (ie, without evidence of progression for at least 2 weeks by repeat imaging \\[note that the repeat imaging should be performed during study Screening\\]), clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n* Has a history of a previous secondary malignancy within 3 years of Screening (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative therapy or other localized, low-grade tumors deemed cured, or whose natural history does not have the potential to interfere with the safety or efficacy assessments of the current study and not treated with systemic anticancer therapy \\[except hormonal therapy\\]).\n* Has a known psychiatric or substance abuse disorder that would interfere with the individuals' ability to cooperate with the requirements of the study.","ALL","18 Years",{"count":19,"type":20},210,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","DBC-664-ONC-101 is a first-in-human Phase 1a\u002F1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.",[26,27,28,29,30,31],"Malignant Germ Cell Tumor","Lung Adenocarcinoma","Gastric\u002FEsophageal\u002FGastroesophageal Junction (GEJ) Adenocarcinoma","Urothelial Carcinoma","Endometrial Adenocarcinoma","Ovarian Adenocarcinoma","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-07-17",{"date":40,"type":20},"2030-04-01",{"name":42,"class":43},"Duboce Biopharmaceuticals, Inc.","INDUSTRY",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":72,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985","NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.",{"count":53,"type":20},5000,"OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[57,58,59,60,61,62,63,64,31,65,30,66,67,68,69,70,71],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Uterine Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[73,74,75,76,77,78,79,80],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","2026-06-29",{"date":83,"type":36},"2026-06-30",{"date":85,"type":36},"2025-04-04",{"date":87,"type":20},"2035-03-31",{"name":89,"class":90},"Dana-Farber Cancer Institute","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":91},"100625965","assessment-of-adherence-to-remotely-monitored-physical-activity-tracked-on-a-smartwatch-and-its-impact-on-reducing-fatigue-3-months-after-adjuvant-chemotherapy-for-cancer-100625965","NCT07429487","Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer","WATCH AND ACT","Inclusion Criteria:\n\n1. Patients aged 18 to 75 years old,\n2. Histologically proven non-metastatic adenocarcinoma of breast, colorectal, ovarian, pancreatic, biliary, or gastric origin,\n3. Adjuvant chemotherapy completed less than 3 months ago (excluding hormone therapy),\n4. PS 0 or 1 according to the World Health Organization (WHO) scale,\n5. No recurrence since the end of adjuvant chemotherapy,\n6. Patient who has voluntarily agreed to participate in the study and sign the written informed consent form,\n7. Patient affiliated with a Social Security scheme.\n\nExclusion Criteria:\n\n1. New cancer treatment planned (excluding hormone therapy),\n2. Patient who has received adjuvant immunotherapy,\n3. Cardiological contraindication to the program\n4. Decompensated or unstable chronic conditions\n5. Severe malnutrition\n6. Rheumatological unfitness as determined by the oncologist,\n7. Chronic respiratory failure requiring long-term O2 therapy\n8. Diabetes with plantar ulceration\n9. Progressive or chronic non-healing bedsore\u002Fwound\n10. Recent unhealed fracture\n11. Patient participating in another interventional clinical study at the time of signing the informed consent form.\n12. Vulnerable persons as defined in Articles L1121-5 to -8","75 Years",{"count":101,"type":20},98,[103],"NA","A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to compare changes in fatigue at 3 months in patients who have completed adjuvant systemic chemotherapy for cancer and are participating in an APA program.",[61,106,31,107,108],"Colorectal Cancer","Pancreatic Cancer","Gastric Adenocarcinoma",[110,111,112],"adapted physical activity","fatigue","completed adjuvant systemic chemotherapy for cancer","NOT_YET_RECRUITING","2026-02-17",{"date":116,"type":36},"2026-02-24",{"date":118,"type":20},"2026-06-15",{"date":120,"type":20},"2030-06-15",{"name":122,"class":90},"Centre Antoine Lacassagne",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":130,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":133,"studyType":54,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":91},"100600653","anatomopathological-analysis-of-the-infundibulopelvic-ligament-in-patients-with-ovarian-cancer-100600653","NCT07100288","Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer","INFPELV","Inclusion Criteria:\n\n* ◦ Patients with epithelial ovarian cancer, including high- and low-grade serous, high- and low-grade endometrioid, mucinous (expansile and infiltrative types), and carcinosarcoma.\n\n  * FIGO 2014 stage IA-IVB.\n  * Patients undergoing primary surgery or interval surgery after 3-4 or 6 cycles of chemtherapy\n  * Patients with no residual disease after surgery.\n  * Patients with ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* ◦ Patients without epithelial ovarian cancer.\n\n  * Patients with ECOG 2-4.\n  * Patients who do not consent to participate in the study.\n  * Patients who did not undergo complete staging surgery (including hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omentectomy) or with residual disease after cytoreductive surgery.","FEMALE",{"count":132,"type":20},200,"2 Years","Involvement of the infundibulopelvic ligament in ovarian cancer may be associated with decreased survival and related to paraaortic lymph node metastasis",[136,137,31],"Ovarian Cancer","Ovarian Cancer (OvCa)","2025-07-27",{"date":140,"type":36},"2025-08-03",{"date":142,"type":36},"2025-07-20",{"date":144,"type":20},"2030-12-30",{"name":146,"class":90},"Complejo Hospitalario Universitario Insular Materno Infantil"]